http://www.pharma-gxp.com/ http://www.pharma-gxp.com/index/ http://www.pharma-gxp.com/member-registration/ http://www.pharma-gxp.com/about-us/ http://www.pharma-gxp.com/fda-483s/ http://www.pharma-gxp.com/non-complaince-reports/ http://www.pharma-gxp.com/articles/ http://www.pharma-gxp.com/presentations/ http://www.pharma-gxp.com/webinars/ http://www.pharma-gxp.com/discussion-topics/ http://www.pharma-gxp.com/news/3-Faces-of-Spreadsheet-Validation/41/ http://www.pharma-gxp.com/news/US-FDA-to-review-new-drug-application-using-Catalent-softgel-drug-delivery-tech/40/ http://www.pharma-gxp.com/news/Government-mulls-providing-over-50-essential-drugs-at-cheaper-rates--/39/ http://www.pharma-gxp.com/news/FDA-updates-label-for-Novartis--MS-pill-Gilenya-after-reports-of-brain-infection/38/ http://www.pharma-gxp.com/gxpnews/ http://www.pharma-gxp.com/view-video.php?id=1 http://www.pharma-gxp.com/view-video.php?id=2 http://www.pharma-gxp.com/view-video.php?id=3 http://www.pharma-gxp.com/view-video.php?id=4 http://www.pharma-gxp.com/view-video.php?id=5 http://www.pharma-gxp.com/view-video.php?id=6 http://www.pharma-gxp.com/view-video.php?id=7 http://www.pharma-gxp.com/view-video.php?id=8 http://www.pharma-gxp.com/view-video.php?id=10 http://www.pharma-gxp.com/view-video.php?id=11 http://www.pharma-gxp.com/view-video.php?id=12 http://www.pharma-gxp.com/view-video.php?id=13 http://www.pharma-gxp.com/view-video.php?id=14 http://www.pharma-gxp.com/view-video.php?id=15 http://www.pharma-gxp.com/view-video.php?id=16 http://www.pharma-gxp.com/view-video.php?id=17 http://www.pharma-gxp.com/view-video.php?id=18 http://www.pharma-gxp.com/news/China-FDA-wants-signed-internal-audits-on-clinical-trial-applications-this-month/37/ http://www.pharma-gxp.com/news/FDA-announces-new-GDUFA-fees-and-says-to-pay-up-by-Oct.-1/36/ http://www.pharma-gxp.com/news/FDA-warning-letter-smacks-Indian-lab-for-repeated-shortcomings-/33/ http://www.pharma-gxp.com/news/French-regulator-found-30-cases-of-mold-contamination-in-biotech-plant-/32/ http://www.pharma-gxp.com/news/Opposing-Views-on-FDA-Complete-Response-Letters/31/ http://www.pharma-gxp.com/news/India-defers-free-trade-agreement-talks-with-EU-over-ban-of-700-pharma-products/30/ http://www.pharma-gxp.com/news/GVK-ban-fallout-India-defers-FTA-talks-with-EU--/29/ http://www.pharma-gxp.com/news/STATEMENT-OF-NON-COMPLIANCE-WITH-GMP-TXCELL-BESANCON,-FRANCE/28/ http://www.pharma-gxp.com/news/WHO-Technical-Report-GMP-for-Biological-Products-Revision/27/ http://www.pharma-gxp.com/news/FDA-483s-and-Responses-available-in-the-World-Wide-Web/26/ http://www.pharma-gxp.com/news/Indian-and-Chinese-API-Manufacturers-in-the-Focus-of-European-Authorities/25/ http://www.pharma-gxp.com/news/EP-Chapter-2.6.27-Microbiological-Examination-of-cell-based-Preparations-revised/24/ http://www.pharma-gxp.com/news/CBER-Considerations-for-the-Design-of-Early-Phase-Clinical-Trials-of-Cellular-and-Gene-Therapy-Pro/23/ http://www.pharma-gxp.com/news/Some-Baidyanath-products-contain-lead-NYC-health-department/22/ http://www.pharma-gxp.com/news/EU-bans-700-generic-drugs-for-manipulation-of-trials-by-GVK-Biosciences/21/ http://www.pharma-gxp.com/news/Summary-Safety-Review-Acetaminophen-Liver-Injury/20/ http://www.pharma-gxp.com/news/WHO-&-UNICEF-release-worldwide-updated-data-on-immunization/19/ http://www.pharma-gxp.com/news/NPPA-revises-prices-of-39-formulations-ranging-from-commonly-used-diabetes-drugs-to-antibiotics/18/ http://www.pharma-gxp.com/news/Will-Bovine-Heparin-Be-Reintroduced-into-the-U.S.-Market-/17/ http://www.pharma-gxp.com/news/Bill-makes-distinction-between-drugs-and-medical-devices-AdvaMed-/16/ http://www.pharma-gxp.com/news/Life-ban-for-founder-of-fake-US-drug-company-with-$12m-in-sales/15/ http://www.pharma-gxp.com/news/AB-Science-hit-with-FDA-warning-letter-over-clinical-trials/14/ http://www.pharma-gxp.com/news/Data-management,-SOP-deficiencies-cited-often-after-2014-GCP-inspections,-EMA-report-finds/13/ http://www.pharma-gxp.com/news/Written-Confirmation-Now-also-Israel-and-Brazil-on-the--Third-Countries-List-/12/ http://www.pharma-gxp.com/news/FDA-Inspection-Reports-What-is-What/11/ http://www.pharma-gxp.com/news/An-Addendum-to-ICH-M7-provides-practical-Examples-to-calculate-compound-specific-Acceptable-Intakes/10/ http://www.pharma-gxp.com/news/GMP-Non-Compliance-to-Regulation-Pharmax-Limited-Ontario,-Canada/8/ http://www.pharma-gxp.com/news/What-Happened-at-the-GDUFA-II-Meeting-and-What-is-Happening-at-OGD-/7/ http://www.pharma-gxp.com/news/Slowdown-in-drug-approvals,-currency-volatility-pose-stern-test-for-Indian-pharma-companies/6/ http://www.pharma-gxp.com/news/DCGI-to-launch-20-mobile-labs,-recruit-200-drug-inspectors-to-strengthen-Central-regulatory-system/5/ http://www.pharma-gxp.com/news/AMRI-looks-to-close-API-facility-in-Wales-as-part-of-network-realignment/4/ http://www.pharma-gxp.com/news/NPPA-issues-Compendium-of-Notified-Ceiling-Prices-of-Scheduled-Drugs-2015/3/ http://www.pharma-gxp.com/news/WHO-issues-draft-guidelines-on-Good-Pharmacopoeial-Practices;-invites-comment-by-March-10/2/ http://www.pharma-gxp.com/news/Asia-Regulatory-Roundup-India-s-Push-for-Regulatory-Consolidation/1/